This implies that the disruption of this interaction by small molecular inhibitors might serve as an alternative strategy for the preferential inhibition of PRMT5 epigenetic functions, which can be exploited as a specific therapy for the cancers in which PRMT5 mediated epigenetic signaling is dysregulated. This evidence concerns the gene PRMT5 and cancer.